GNMSF
Price
$198.51
Change
-$6.49 (-3.17%)
Updated
Jul 3 closing price
Capitalization
12.61B
RIGL
Price
$18.93
Change
+$0.28 (+1.50%)
Updated
Jul 3 closing price
Capitalization
338.33M
Interact to see
Advertisement

GNMSF vs RIGL

Header iconGNMSF vs RIGL Comparison
Open Charts GNMSF vs RIGLBanner chart's image
Genmab A/S
Price$198.51
Change-$6.49 (-3.17%)
Volume$24
Capitalization12.61B
Rigel Pharmaceuticals
Price$18.93
Change+$0.28 (+1.50%)
Volume$97.44K
Capitalization338.33M
GNMSF vs RIGL Comparison Chart in %
Loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNMSF vs. RIGL commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNMSF is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (GNMSF: $198.51 vs. RIGL: $18.93)
Brand notoriety: GNMSF and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNMSF: 14% vs. RIGL: 47%
Market capitalization -- GNMSF: $12.61B vs. RIGL: $338.33M
GNMSF [@Biotechnology] is valued at $12.61B. RIGL’s [@Biotechnology] market capitalization is $338.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNMSF’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • GNMSF’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, GNMSF is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNMSF’s TA Score shows that 3 TA indicator(s) are bullish while RIGL’s TA Score has 3 bullish TA indicator(s).

  • GNMSF’s TA Score: 3 bullish, 4 bearish.
  • RIGL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GNMSF is a better buy in the short-term than RIGL.

Price Growth

GNMSF (@Biotechnology) experienced а -5.96% price change this week, while RIGL (@Biotechnology) price change was +0.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

RIGL is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($12.6B) has a higher market cap than RIGL($338M). GNMSF has higher P/E ratio than RIGL: GNMSF (11.65) vs RIGL (9.06). RIGL YTD gains are higher at: 12.545 vs. GNMSF (-4.279). GNMSF has higher annual earnings (EBITDA): 1.35B vs. RIGL (48.5M). GNMSF has more cash in the bank: 3.23B vs. RIGL (77.1M). RIGL has less debt than GNMSF: RIGL (61.1M) vs GNMSF (143M). GNMSF has higher revenues than RIGL: GNMSF (3.12B) vs RIGL (203M).
GNMSFRIGLGNMSF / RIGL
Capitalization12.6B338M3,728%
EBITDA1.35B48.5M2,788%
Gain YTD-4.27912.545-34%
P/E Ratio11.659.06129%
Revenue3.12B203M1,534%
Total Cash3.23B77.1M4,184%
Total Debt143M61.1M234%
FUNDAMENTALS RATINGS
GNMSF vs RIGL: Fundamental Ratings
GNMSF
RIGL
OUTLOOK RATING
1..100
3061
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
42100
PRICE GROWTH RATING
1..100
6044
P/E GROWTH RATING
1..100
93100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (57) in the null industry is in the same range as RIGL (76) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

GNMSF's Profit vs Risk Rating (100) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

GNMSF's SMR Rating (42) in the null industry is somewhat better than the same rating for RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's Price Growth Rating (44) in the Biotechnology industry is in the same range as GNMSF (60) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (93) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNMSFRIGL
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TDCB8.900.38
+4.46%
Third Century Bancorp
OSGSF24.57N/A
N/A
Osaka Gas Co.
RTOBF3.60N/A
N/A
Ratos AB
LGDTF0.24-0.01
-2.97%
Liberty Gold Corp
NAUBF24.53-1.47
-5.65%
National Australia Bank Ltd. (Victoria, Australia)

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
-3.17%
GMAB - GNMSF
58%
Loosely correlated
-0.68%
RIGL - GNMSF
29%
Poorly correlated
+1.50%
ARCT - GNMSF
28%
Poorly correlated
+1.17%
ATNM - GNMSF
27%
Poorly correlated
+0.70%
AGIO - GNMSF
27%
Poorly correlated
+2.04%
More